The drug Gabapentin is occasionally prescribed to help control hot flashes resulting from hormone deprivation therapy (ADT). Today, Aurobindo Pharma USA, Inc. issued a voluntary nationwide recall of their Northstar Labeled Gabapentin Capsules, USP 300 mg 100 count bottle. The recall was issued on complaints about empty capsules in prescriptions received by patients. There is [...]
In the normal course of events node-positive prostate cancer has typically been excluded from clinical trials. This leaves our oncologists with little evidence to guide the management for those of us who have this flavor of prostate cancer. A recent anaylisis presented at the European Society for Medical Oncology (ESMO) 2014 Congress begins to shed [...]
Androgen deprivation therapy (ADT) and bone complications are the two near universals for men with advanced prostate cancer. A long-term follow up of fifteen (15) years after diagnosis of a population-based cohort of prostate cancer survivors proved to be very informative. The Prostate Cancer Outcomes Study, which enrolled 3533 men diagnosed with prostate cancer between [...]
Bayer Healthcare has announced that they will be resuming production of Xofigo® (radium Ra 223 dichloride) for new patients beginning on Monday, November 17th. Xofigo is the newly FDA approved radiopharmaceutical treatment for men with castrate resistant metastatic prostate cancer (mCRPC) with bone metastases without any known visceral metastases. On October 8, 2014 Bayer informed [...]
It was announced this morning that Dendreon (the manufactures of Provenge) has filed for voluntary Chapter 11 Bankruptcy. After having spoken with a representative at Dendreon I have learned that the company has been in negotiations with its creditors and agreed to voluntarily file for financial reorganization. The agreement that Dendreon has reached with their [...]